Expression of vascular endothelial growth factors VEGF-C and -D, VEGFR-3, and comparison of lymphatic vessels density labeled with D2-40 antibodies as a prognostic factors in vulvar intraepithelial neoplasia (VIN) and invasive vulvar cancer by Jach, Robert et al.
To cite this article: Neuroendocrinol Lett 2011; 32(4):530–539
O
R
I
G
I
N
A
L
 
A
R
T
I
C
L
E
Neuroendocrinology Letters Volume 32 No. 4 2011
Expression of vascular endothelial growth 
factors VEGF-C and -D, VEGFR-3, and 
comparison of lymphatic vessels density 
labeled with D2-40 antibodies as a prognostic 
factors in vulvar intraepithelial neoplasia 
(VIN) and invasive vulvar cancer 
Robert Jach 1, Grzegorz Dyduch 2, Małgorzata Radoń-Pokracka 1, 
Paulina Przybylska 1, Marcin Mika 1, Joanna Dulińska-Litewka 3, 
Krzysztof Zając 1, Hubert Huras 1, Joanna Streb 4, Klaudia Stangel-Wójcikiewicz 1, 
Olivia Dziadek 1, Bartlomiej Galarowicz 1
1  Department of Obstetrics and Gynecology, Jagiellonian University Medical College, Kraków, Poland
2  Department of Pathology, Jagiellonian University Medical College, Kraków, Poland 
3  Department of Medical Biochemistry Jagiellonian University Medical College, Kraków, Poland 
4  Department of Oncology, Jagiellonian University Medical College, Kraków, Poland
Correspondence to: Robert Jach, MD.
Department of Obstetrics and Gynecology, Jagiellonian University Medical College
23 Kopernika str., 31-501 Krakow, Poland.
tel: +48 12 4248560; fax: +48 12 4248584; e-mail: jach@cm-uj.krakow.pl
Submitted: 2011-05-10 Accepted: 2011-06-15 Published online: 2011-08-29
Key words:  VIN;  vulvar intraepithelial neoplasia;  vulvar squamous cell carcinoma; 
 vascular endothelial growth factor;  density of lymphatic vessels
Neuroendocrinol Lett 2011; 32(4):530–539 PMID: 21876509   NEL320411A08  © 2011 Neuroendocrinology Letters • www.nel.edu
Abstract OBJECTIVE: The aim of this study was to compare the immunohistochemical 
expression of vascular endothelial growth factors VEGF-C and D, as well as the 
expression of VEGFR-3 in VIN and vulvar invasive cancer and to compare the 
density of lymphatic marker D2-40 antibody in both groups, and to compare 
them with different clinicopathologic features.
MATERIALS & METHODS: The study was performed using tissue material and 
clinical data from 100 women diagnosed with VIN and 100 women diagnosed 
with invasive vulvar cancer.
RESULTS: No significant differences were found in the expression of VEGF-C 
and -D or VEGFR-3 between those patients with VIN and those with invasive 
vulvar cancers. Weak expression of VEGF-C was confirmed only in two cases 
of the analyzed series; in all cases, expression of VEGF-D and VEGFR-3 was 
observed. The strongest expression of VEGF-D and VEGFR-3 was observed in 
the group of invasive cancers. The highest density of lymphatic vessels per 2 mm 
was observed in VIN. In the cancer group, small lymphatic vessels with a narrow 
oval lumen were observed. Moreover, in two cases of vulvar cancer, the presence 
of intratumoral lymphatic vessels was observed.
CONCLUSIONS: These results suggest that lymphangiogenesis begins at the pre-
invasive stage of vulvar carcinogenesis and suggests the important role of VEGF-
C, VEGF-D, VEGFR-3 and LV (D2-40) as prognostic factors in the process of 
carcinogenesis in the vulvar area.
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INTRODUCTION
Vulvar cancer consists of 2.5–5% of all cancers of the 
female genital tract. Poland is a country with an average 
occurrence of this tumor. Most women suffer from this 
disease between the ages of 60 and 70 years. Recently 
conducted epidemiological studies indicate that the inci-
dence of intraepithelial neoplasia and vulvar cancer is 
increasing particularly in women under 50 years of age. 
The epidemiological model of vulvar cancer in young 
women involves the role of sexually transmitted infec-
tions (sexually transmitted diseases), especially HPV 
infection with high oncogenic potential, such as HPV 16, 
18, 45, 56, 66 and 69; also considered is the importance 
of habitual smoking in the process of disease genesis. 
In older women, vulvar cancer coexists in a high 
percentage of cases with hyperplasia, lichen sclerosus 
and squamous cell carcinoma. In 60% of women, vulvar 
cancer develops in the labia majora, to a lesser percent-
age of the labia minora, the clitoris and posterior labial 
commissure. The method of choice in the treatment of 
vulvar cancer is surgery. Radiation and chemotherapy 
treatment are usually combined with surgical treatment. 
Radical excision of the vulva, together with regional 
lymph nodes, is an operation that involves early and 
late complications (Judson et al. 2006). Removal of 
lymph nodes in which metastatic cells are present leads 
to a reduction in tumor mass, which can have a posi-
tive therapeutic effect. Cancer metastases present in 
the lymph nodes removed (lymphadenectomy) is also 
important for the final classification of the clinical stage 
of cancer and to decide on how to continue therapy.
Histopathologic assessment of lymph nodes removed 
in the vulvar cancer operation shows that metastatic 
cancer cells are found in the grade I stage of cancer 
in about 16%, grade II clinical stage in about 36%, an 
average of approximately 28 to 33% of cases. Thus, in 
approximately 70% of the women operated on with 
vulvar cancer, whereby there is no evidence of metas-
tasis to the lymph nodes, removal does not improve 
treatment results (Markowska 2006). Furthermore, 
the removal of normal lymph nodes may also have an 
adverse impact on the local immune status, which is 
important to the treatment of cancer.
Vulvar intraepithelial neoplasia (VIN) and its clas-
sification remains controversial. There are currently 
three systems of classification VIN: 
1. The 3-staged, WHO classification system: VIN1-3
2. The Bethesda system type classification, two-staged, 
dividing the low-VIN and high degree VIN, and 
3. The 2004 established ISSVD classification (Inter-
national Society for the Study of Vulvovaginal Dis-
ease) does not stage VIN. The incidence of VIN has 
increased in recent decades, while the incidence of 
invasive vulvar cancer has remained at the same level 
or even declined in some countries. For example, the 
U.S. prevalence of VIN3 (vulvar carcinoma in situ) 
increased by 411% between 1973 and 2000, while the 
incidence of invasive vulvar cancer increased by only 
20% during the same period of time (Judson et al. 
2006).
Women with the immunodeficiency virus are 
approximately four times more vulnerable to HPV 
infection. However, the incidence of VIN in HIV-posi-
tive women ranges from 0.5 to 37% (Kuhn et al. 1999). 
Thus, a high percentage of HIV infection in women 
with VIN suggests recommended HIV testing for 
women with VIN. The lifetime risk of developing inva-
sive cancer in women previously treated for VIN3 is 
between 2.5–7% (Iversen & Treli 1998; Jones & Rowan 
1994; Thuis et al. 2000). (Figure 1).
VIN is also an independent predictor of relapse 
(relative risk 3.06) as demonstrated in a study of 101 
patients and 33 recurrences Preti (Preti et al. 2000).
In recent years, it has been observed that there is 
an increased incidence of vulvar cancer in women of 
younger ages leading to the search for less radical, but 
also effective surgical methods. These methods have 
allowed, on one hand, the reduction of injury, reduction 
of surgery time and reduction in the rate of postopera-
tive complications and importantly, improvement in the 
quality of life for these women. To achieve this goal, it is 
equally important to recognize new prognostic factors, 
among which molecular factors are an attractive model, 
both in terms of diagnostics and therapeutic potential.
Lymphatic vessels play a key role in the spread of 
cancer. In recent years, several markers have been 
identified specific for lymphatic endothelium, which 
allowed for improved knowledge of the interaction 
between lymph vessels and lung cancer, but many issues 
in relation to their prognostic significance remains 
unclear (Judson et al. 2006, Markowska 2006).
Proteins belonging to the family of glycoprotein 
endothelial growth factor (VEGF), referred to as 
VEGF-C and VEGF-D, are considered the most impor-
tant regulatory factors in lymphangiogenesis. These fac-
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Fig. 1. VIN 2/3 incidence .
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tors are potent mitogens to the lymphatic and vascular 
endothelium. Furthermore, VEGF-C causes an increase 
in vascular permeability. These regulatory factors are 
ligands for the receptor VEGFR-3, whose expression is 
restricted to the endothelium of lymphatic vessels, and 
in the formation of blood vessels during embryogene-
sis. Factors VEGF-C and VEGF-D have been identified 
as stimulators of lymphatic endothelial proliferation, 
acting through the activation of the receptor
3 VEGF (VEGFR-3), which functions as a specific 
receptor in mature tissues and shows strong expres-
sion within the endothelial cells (Wissmann & Detmar 
2006; Najda & Detmar 2006). Many clinical studies 
have shown a positive correlation between expression 
of VEGF-C and VEGF-D in the primary tumor and 
lymph node metastases (Donoghue et al. 2007; Nisato 
et al. 2003).
The aim of the study is to compare the immunohis-
tochemical expression of vascular endothelial growth 
factors VEGF-C and D, and the expression of VEGFR-
3, in VIN and vulvar invasive cancer, and to also com-
pare the density of lymphatic marker D2-40 antibody 
in both groups, as prognostic factors, and to compare 
them with other clinicopathologic features.
MATERIAL
The study was based on tissue material obtained during 
surgical procedures performed in the Department of 
Gynecology and Oncology at Jagiellonian University 
from 2006–2008. This tissue was in the form of cubes 
stored in paraffin, kept in the archives of the Depart-
ment of Pathology. The clinical data of patients treated 
was obtained from the Department of Gynecology 
and Obstetrics. (Figures 2–6). The material was fixed 
in formalin on a routine basis. The analysis included 
100 cases of vulvar dysplasia (30 – VIN I, 10 – VIN2, 
60-VIN3) of which the average age of the patient was 
65 years, and 10 cases of vulvar cancer of which the 
average age was 71 years. Patients were observed in the 
Gynecology Oncology Clinic of Jagiellonian Univer-
sity, Krakow from 12 to 48 months. At intervals of 4–6 
months, patients were evaluated by history and physi-
cal examination, undergoing cytologic-colposcopic 
screening, and assessment of HPV DNA. In case of 
recurrence, a second operation was performed. The 
average age of women with vulvar cancer was 71.1 
(59–79) years of age and was significantly higher than 
the average age of women with VIN, which was 56.6 
(43–78) years at p=0.003. (Table 1, Figure 7)
METHODOLOGY
The diagnosis of VIN and vulvar cancer was based on 
histological evaluation of specimens taken from the 
vulva with guidance of the colposcope. In every case, 
specimens were also assessed in the presence of the 
HPV DNA test using Hybrid Capture II (DIGENE 
Corp.) with the material taken directly from the vulvar 
brush made of Dacron. The sample was also assessed 
histologically for metastasis in lymph nodes (superficial 
inguinal and deep) collected bilaterally in all 100 cases 
of vulvar cancer and 100 cases of VIN (clinically exam-
ined enlarged lymph nodes) during surgical treatment.
For immunohistochemical studies, samples were 
selected individually and made into paraffin blocks, 
each representative of a specific case. 
From the selected paraffin cubes, 4 microns thick, 
samples were placed on glass slides coated with 
silanized basic Super Frost + (SuperFrost Inc.). Depa-
rafinization involved placing the sample for 10 min-
utes in xylene and then dehydrated lead through three 
changes of ethyl alcohol of increasing concentration 
(70%, 86% and 96%), each lasting 5 minutes. In order 
to inhibit endogenous peroxidase activity, preparations 
were placed for 10 min in 3% H2O2 solution. Antigen 
unmasking was achieved by heating in a microwave 
oven Whirlpool, 3 times for 5 minutes in a 750 W 
preparation placed in citrate buffer (pH 6.0, 0.01 M), or 
EDTA buffer (pH 8.0, 0.01 M).
After incubation, preparations were washed with 
TBS buffer (50 mM Tris-Hcl, 150 mM NaCl, pH 7.6, 
DAKO Corporation). To visualize the antigen-antibody 
complex, we used the En Vision system (DAKO Cor-
poration) and Lab Vision (LabVision) (see the table) 
with 3-amino-9-ethylcarbazole (AEC) (DAKO Corpo-
ration) as a chromogen. Nuclei were contrasted with 
Mayer Hematoxylin for 1 minute and then covered with 
slide coverslips in glycerol. Basic data on the antibody 
used in the work is presented in Table 2.
Positive control preparations were: tonsil – for 
D2-40, placenta- for VEGFR-3 and VEGF-C and 
VEGF-D, ductal carcinoma of the breast – for VEGF-C 
and VEGF-D, the small intestine – for D2-40. Negative 
controls were the same antibody preparations as the 
original. 
Evaluation of immunohistochemistry 
Lymphatic vessel density was evaluated using high 
power (40×). (Figures 8–10) All D2-40 positive vessels 
within the area of 0,5mm width beneath the dysplastic 
epithelium (VIN) or invasive edge of the tumor were 
counted and the result has been provided. All vessels 
Tab. 1. Characteristics of women studied with VIN and vulvar 
cancer. 
Type n Average mean SD min max p-value
VIN3 60 56.0 14.4 43 78
VIN2 10 67.0 67 67
VIN1 30 54.3 3.8 50 57
All Grps VIN 100 56.6 11.5 43 78
p=0.003
Ca 100 71.1 7.2 59 79
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were counted and the result is given as the number of 
vessels per 2mm. (Figures 11 and 12).
The staining for VEGF-C, VEGF-D, and VEGFR-3 
expression was assessed by semiquantitative method, at 
high (400×) magnification. The severity of expression 
was evaluated on a scale from 0 to 3; 0 – lack of stain-
ing, 1 – weak, 2 – moderate, 3 – strong). The number 
of cells expressing VEGF-C and D and VEGFR-3 were 
classified to four groups: 0 – no staining or staining in 
individual cells at the edge of the preparation, 1 – less 
than 20% positive cells, 2 – 20–50%, 3 – above 50%. 
Points earned for staining intensity and number of posi-
tive cells finally summed 4 groups:
0: 0–1 points 
I: 2–3 points 
II: 4 points 
III: 5–6 points 
RESULTS 
The results are presented in Tables 3–10. The statisti-
cal analysis (statistical package Statistica 8.0, Statsoft. 
Inc. USA) showed no significant differences in the 
expression of VEGF-C and D and VEGFR-3 between 
the VIN group and invasive vulvar cancer group. Weak 
expression of VEGF-C was found only in two cases of 
the analyzed series, and in all cases, the expression of 
VEGF-D and VEGFR-3 was observed. The strongest 
expression of VEGF-D and VEGFR-3 was observed in 
the group of invasive cancers. Similarly, the differences 
in the amount of lymphatic vessels between the group 
of invasive cancers and VIN group did not reach statis-
tical significance. 
The highest density of lymphatic vessels per 2 mm 
was observed in VIN. In this group, and in most cases, 
sections of lymphatic vessels were irregular and slightly 
expanded. In the cancer group, we observed small lym-
phatic vessels with a narrow, oval lumen. Moreover, in 
two cases, the presence of lymphovascular space inva-
sion (LVSI) was observed. 
The evaluation of recurrence in women treated 
showed a statistical difference between the group VIN3 
and VIN1 at p=0.058 (ie. 5.8%, with the conclusion that 
VIN3 and VIN1 differ by the presence of recurrence), 
which is an interesting trend and needs further investi-
gation in more cases, with specific attention to the lit-
erature citing similar occurrence of relapses and VIN1 
and VIN2 / 3 (Table 7). 
Tab. 2. Antibodies, their dilution, and incubation time.
Antibody Type Clone Manufact urer Dilution Unmasking Time Detection system
VEGFR-3 monoclonal KLT9 Novocastr a 1:50 microwave EDTA, pH=8.0 60 min Lab Vision
VEGF-C polyclonal Santa Cruz 1:100 microwave EDTA, pH=8.0 12 hrs En Vision
VEGF-D monoclonal 78923 R&D systems 1:200 microwave EDTA, pH=8.0 12 hrs En Vision
D2-40 monoclonal D2-40 Covance Ready-to-use microwave citrate buffer, pH=6.0 30 min En Vision
Fig. 2 Fig. 3 Fig. 4
Fig. 5 Fig. 6
Fig. 2. VIN3 clinical manifestation.
Fig. 3. Vulvar cancer. Clinical presentation.
Fig. 4. Metastatic inguinal lymphnodes in 
vulvar cancer.
Fig. 5. Postoperative speciemen
Fig. 6. Clinical presentation after surgery in 
vulvar cancer.
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The median survival time without recurrence was 
the longest in the group of patients with vulvar cancer, 
in which it was followed by 45.2 months; in women 
with VIN, it was followed by 37.2 months The shortest 
survival time without recurrence was among women 
with VIN3-28.7 months, 95% CI (Table 10). In our 
opinion, this trend may result from the heterogeneity of 
women diagnosed with VIN3, location and multiplicity 
of the disease. 
Disease-free survival curves were compared using 
log-rank tests. There were no statistically significant dif-
ferences between survival without recurrence in groups 
of Ca. and VIN. Two-year survival among patients with 
VIN was 60%, and for patients with vulvar cancer, 70% 
(Figure 13). No statistically significant differences in 
the prevalence of HPV DNA in the test groups and the 
presence of lymph node metastases in the groin were 
observed. (Tables 8 and 9).
DISCUSSION
Lymphatic vessels play a key role in the spread of cancer. 
In recent years, several markers specific to lymphatic 
endothelium have been identified, which allowed for 
a deeper insight into the relationship between lymph 
vessels and cancer, although there are still a lot of ques-
tions for which there is no clear answer (Hillen & Grif-
fioen 2007; Sundar & Ganesan 2007).
The idea that cancer cells spread to already exist-
ing lymphatic vessels is still present in the literature, 
although it seems that there is a belief about the pres-
ence of active lymphangiogenesis in tumors (Beasley et 
al. 2002; Maula et al. 2003; Nathanson 2003). Currently, 
though one does not deny the presence of lymphatic ves-
sels in tumors, the problem of the existence of active lym-
phangiogenesis, and the prognostic value of lymphatic 
vessel density inside or at the periphery of the tumor has 
not been completely resolved (Nathanson 2003; Stacker 
et al. 2001; Ji 2006). The functionality of the lymphatic 
vessels, and their role in metastasis is the subject of dis-
cussion (Maula et al. 2003;Ji 2006; Padera et al. 2002).
In the presence of primary tumors, the extent of 
lymphangiogenesis can serve as a prognostic indica-
Tab. 3. Expression of VEGF-C in studied groups of women.
DGN n
VEGF-C
0 1
VIN3
60
30 30
50.00% 50.00%
VIN2
10
10 0
100.00% 0.00%
VIN1
30
30 0
100.00% 0.00%
All Grps VIN
100
70 30
70.00% 30.00%
CA
100
90 10
90.00% 10.00%
Tab. 4. Expression of VEGF-D in groups of women studied.
DGN n
VEGF-D
0 1 2 3
VIN3 60 10 20 30 0
16.67% 33.33% 50.00% 0.00%
VIN2 10 0 10 0 0
0.00% 100.00% 0.00% 0.00%
VIN1 30 20 1 0 0
66.67% 33.33% 0.00% 0.00%
All Grps 
VIN
100 30 40 30 0
30.00% 40.00% 30.00% 0.00%
CA 100 0 30 60 10
0.00% 30.00% 60.00% 10.00%
Tab. 5. Expression of VEGFR-3 in the studied groups of women.
DGN n
VEGFR-3
0 1 2 3
VIN3 60 0 0 60 0
0.00% 0.00% 100.00% 0.00%
VIN2 10 0 0 0 10
0.00% 0.00% 0.00% 100.00%
VIN1 30 0 20 10 0
0.00% 66.67% 33.33% 0.00%
All Grps 
VIN
100 0 20 70 10
0.00% 20.00% 70.00% 10.00%
CA 100 10 0 30 60
10.00% 0.00% 30.00% 60.00%
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Fig. 7. Age distribution in VIN and vulvar cancer.
tor of survival. A positive correlation is observed in the 
density of lymphatic vessels with lymph node metas-
tasis; this has been reported in cases of squamous cell 
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et al. 2005). In prostate cancer, or in some case series of 
breast cancer, there was no opportunity to determine 
the presence of lymphatic vessels inside the tumor. A 
lot of work highlights significant changes in the lymph 
vessels – the proliferation, budding of new blood vessels 
and expansion in the vicinity of the tumor. 
As in physiological conditions, vascular growth fac-
tors VEGF-C and-D, activating receptor VEGFR-3, play 
an essential role in this process. VEGF-C and-D exhibit 
lymphangiogenic functions through the stimulation of 
VEGFR-3. They are produced as pre-propeptides that 
undergo proteolytic processing in the extracellular 
matrix. Their mature forms exhibit a greater affinity 
for VEGFR-3, but can also bind VEGFR-2 and induce 
angiogenesis. Overexpression of VEGF-C and -D in 
experimental tumor models was accompanied by inten-
sive growth of new lymphatic vessels (Skobe et al. 2001), 
but in human tumors, these molecules involved in 
angiogenesis and lymphangiogenesis, are a controver-
sial subject. Some authors state a significant correlation 
between expression of VEGF-C and -D and lymphan-
giogenesis and lymph node status, as well as an increase 
in the density of blood vessels in tumors (Mohammed 
et al. 2007; Nakamura et al. 2003; Nakamura et al. 2003) 
although there are also works in which this relationship 
is not stated (Currie et al. 2004). 
In the mouse model of VEGF-C and VEGF-D 
secreted by tumor cells, there is induced formation of 
lymphatic vessels in, and around the tumor, which pro-
Tab. 6. The density of D2-40 vessel in the examined groups of 
women.
Identification n
D2-40
p-valueAverage
mean SD min max
VIN3 6 4.88 0.81 4.0 6.0
VIN2 1 3.90 3.9 3.9
VIN1 3 2.00 0.00 2.0 2.0
All Grps VIN 10 3.92 1.49 2.0 6.0
NS
Ca 10 3.80 1.76 1.7 7.0
carcinoma of the head and neck (Beasley et al. 2002), 
gastric carcinomas (Kitadai et al. 2005) and pancreatic 
tumors (Rubbia-Brandt et al. 2004). In breast cancer, 
no correlation has been found between the number of 
lymphatic vessels and lymph node status, to the survival 
of patients (Bono et al. 2004). The multivariate analysis 
showed that high-density peritumoral lymphatic vessels 
were associated with higher risk of metastasis to lymph 
nodes in squamous cell carcinomas of the head and 
neck (Kyzas et al. 2005). In other studies, no correlation 
was found between the density of lymphatic vessels and 
lymphatic vessel invasion, lymph node status, and sur-
vival of patients as in cases of hepatocellular carcinoma 
and pancreatic cancer (Mouta Carreira et al. 2001; Sipos 
Fig. 8. Histologic picture of VIN I. Immunohistochemical staining with D2-40 antibody. Magnification 40x.
Fig. 9. VIN II . Small lymphatic vessels. Immunohistochemical staining with D2-40 antibody. Magnification 40x.
Fig. 10. Histologic picture of VIN. Strong VEGF-D expression in dysplastic epithelium. VEGF-D positive, magnification 40x.
Fig. 11. Histologic picture of vulvar cancer. Irregular single lymphatic vessels. Immunohistochemical staining with D2-40 antibody. 
Magnification 40x.
Fig. 12. Histologic picture of vulvar cancer. Strong VEGF-D expression in infiltrating vulvar cancer cells. Magnification 40x.
Fig. 8 Fig. 9 Fig. 10
Fig. 11 Fig. 12
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motes the development of metastasis to regional lymph 
nodes. These processes have undergone deceleration 
under the influence of antibodies against VEGFR-
3, blocking the activity of the ligands VEGF-D and 
C (Kitadai et al. 2005). Expression of VEGF-C was 
observed in many human cancers: breast cancer, cer-
vical and bronchial and prostate and stomach cancers 
(Roskoski 2007).
In a study of a small number of patients, including 
17 cases of VIN and 26 cases of vulvar cancer, MacLean 
and colleagues demonstrated the presence of VEGF in 
96% of vulvar cancer and only 6% of cases of VIN, not 
expressing this factor in healthy tissue (MacLean et al. 
2000). In experimental models, tumor cells exhibiting 
overexpression of VEGF-C induced the formation of 
lymphatic vessels around the tumor (Saharinen et al. 
2004; He et al. 2004). An additional issue is the rela-
tionship of lymphangiogenesis parameters such as den-
Tab. 7. Presence of recurrences in examined groups of women.
Identification n
Recurrence
p-value
NO YES
VIN3 6 2 4
33.33% 66.67%
VIN2 1 1 0
100.00% 0.00%
VIN1 3 3 0
100.00% 0.00%
All Grps VIN 10 6 4
p=0.639
60.00% 40.00%
CA 10 7 3
70.00% 30.00%
Tab. 10. Comparison of average survival time without recurrence in 
the treated groups of patients.
Group Median survival time without recurrence
95% CI (95% Confidence 
Interval)
VIN3 28.7 mos. 14.4–43.0 mos.
VIN 37.2 mos. 25.8–48.6 mos.
Ca 45.2 mos. 37.6–52.8 mos
Tab. 8. Presence of metastasises in examined groups of women.
Indentification n
Metastasises to lymph 
nodes p-value
NO YES
VIN3 6 6 0
100.00% 0.00%
VIN2 1 1 0
100.00% 0.00%
VIN1 3 3 0
100.00% 0.00%
All Grps VIN 10 10 0
p=0.136
100.00% 0.00%
CA 10 8 2
80.00% 20.00%
Tab. 9. Presence of HPV DNA in examined groups of women.
Identification n
HPVDNA
NO Yes  
VIN3 6 2 4
33.33% 66.67%
VIN2 1 1 0
100.00% 0.00%
VIN1 3 2 1
66.67% 33.33%
All Grps VIN 10 5 5
p=0.65350.00% 50.00%
CA 10 6 4
sity of lymph vessels, VEGF-C and -D, and invasion of 
lymphatic vessels in tumor progression and prognosis. 
In numerous trials, there has been a positive correla-
tion between expression of VEGF-C and the invasion of 
lymphatic vessels, the presence of lymph node metasta-
ses and survival (He et al. 2004). Increased expression of 
VEGF-D was observed in breast, colorectal, gastric and 
thyroid multiforme and gliomas, and it has a positive 
correlation with the presence of lymph node metastases 
as reported in colorectal cancer, ovarian and bronchus 
(Roskoski 2007). In malignant melanoma, VEGF-D 
likely has an important role both in lymphocytes and 
angiogenesis (Achen et al. 2001). Similarly, in many 
tumors, there has been a significant positive correla-
tion between expression of VEGF-C, -D in the primary 
tumor and lymph node status. However, in highly dif-
ferentiated gastric cancers, this association is not found, 
and in cases of breast cancer and small cell lung cancer 
the results were inconclusive.
Increased expression of VEGF-C is a negative prog-
nostic factor in many types of cancer, with the excep-
tion of Neuroblastoma, pancreatic cancer and colon 
cancer. A statistically significant correlation between 
VEGF-D expression in tumors and shorter overall 
survival was observed in endometrial cancer, ovarian 
and pancreatic cancers, in contrast to breast cancer or 
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Fig. 13. Recurrence-free survival rate in cancerous and VIN patients. 
colorectal cancer (Thiele & Sleeman 2006). Expression 
of VEGF-C in tumor cells in many types of cancer gen-
erally increases the risk of spread to the lymph nodes, 
and has some negative effect on survival (Hirakawa et 
al. 2007).
In gynecological tumors, one also considers the 
characteristics of lymphangiogenesis. In cervical 
cancer, a higher density of lymphatic vessels is observed 
in the periphery of the tumor and in the interior of 
the tumor in comparison with the normal cervix. The 
density of blood vessels in the periphery of the tumor 
correlates positively with higher tumor stage, lym-
phatic vessel invasion and metastases to lymph nodes, 
also an independent prognostic factor in multi-and 
one-dimensional analysis (Gombos et al. 2005). New 
development of lymphatic vessels has already been con-
cluded in the early stages of carcinogenesis in cervical 
cancer. Longatto-Filho and colleagues observed that 
higher density of lymphatic vessels was characterized by 
changes in invasive cancers (squamous cell carcinoma 
and adenocarcinoma) compared with changes in pre-
invasive cancers (CIN I, CIN II, CIN III). However, not 
found in this study, was a statistically significant cor-
relation between lymphatic vessel density and lymph 
node status (longatto-Filho et al. 2007). A widely used 
marker of lymphatic vessels is the D2-40. The expres-
sion of this marker was also found in cancer cells and 
cervical epithelium with features of CIN. Although 
D2-40 expression in the epithelium did not correlate 
with clinical features and histological changes, a signifi-
cant relationship between low expression of D2-40 with 
invasion of lymphatic vessels and metastases in lymph 
nodes was observed. This may suggest participation of 
M2A antigen recognized by D2-40 in the interaction of 
tumor cells and endothelial cells of lymphatic vessels 
(Dumoff et al. 2005).
Similarly, expression of vascular growth factors 
essential for lymphangiogenesis in tumor cells is a phe-
nomenon often described in cases of cervical cancer 
(Ueda et al. 2001). Increased expression of VEGF-C is 
attributed to the formation of lymph node metastases 
(Hashimoto et al. 2001).
A clear and statistically significant difference in 
the expression of VEGF-C and -D and their receptor 
VEGFR-3 was observed between (changes in) CIN I and 
CIN II, CIN III and invasive cancer. A higher degree of 
dysplasia was associated with increased expression of 
growth factors and their receptors. This may suggest, 
in addition to pro-lymphangiogenic activity, autocrine 
effects of VEGF-C and -D directly on tumor cells via 
receptor VEGFR-3 (Van Trappen et al. 2003). In cases of 
vulvar cancer and VIN-type changes described, we see 
the adverse effect that lymphangiogenic factors have on 
prognosis and their relationship with the progression 
of dysplastic lesions (Näyhä & Stenbäck 2007; Lewy-
Trenda et al. 2005). For many years, it was believed that 
the true VIN3 precursor of invasive vulvar cancer, cre-
ated a higher risk for women over 40 years of age. Time 
from VIN3 diagnosis to invasive cancer is estimated to 
be about 4 years (1.1 to 7.3). 
Recently, dominated by many views and defended by 
clinical data, is the belief that the potential for malig-
nant changes in low grade VIN does not fully reflect the 
true behavior of these changes, but rather the survival 
of patients with this disease. (Rotmensch & Yamada 
2003; Van seters et al. 2005; Jones et al. 2005). However, 
there are few reports analyzing the parameters of lym-
phangiogenesis in these diseases. In the present study, 
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the presence of lymphatic vessels was observed along 
with changes in the type and degree of dysplasia. It 
was also found that expression of VEGF-C, VEGF-D 
and VEGFR-3 in both groups was correlated with the 
progression of the disease. No statistically significant 
difference between groups is most likely related to the 
small size of the analyzed series.
Taking into account the fact that lymph node involve-
ment is an important prognostic factor in vulvar cancer 
(Raspagliesi et al. 2006), also having been described in 
other tumor lymphangiogenesis parameters, there is a 
strong gynecological association with progression and 
prognosis (Bednarek et al. 2008; Bednarek et al. 2009). 
One would expect that with vulvar cancer precursors 
and changes toward progressive disease, it is possible to 
determine similar relationships. Therefore, also bear-
ing in mind the small number of publications on this 
matter, it seems that further analysis of lymphangio-
genesis in the present group of cases of vulvar cancer 
is justified and purposeful. Due to the relatively small 
number of studies that have examined biomarkers 
(VEGF-C, VEGF-D and VEGFR-3) in carcinogenesis 
of the vulvar area and the lack of multivariate analysis 
in these studies, and taking into account the presence 
of small vulvar cancer and its precursors, you can not 
establish clear conclusions regarding their prognostic 
value.
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